Author Correction: Neoadjuvant Atezolizumab for Resectable Non-Small Cell Lung Cancer: An Open-Label, Single-Arm Phase II Trial

Authors

Jamie E Chaft
Filiz Oezkan
Mark G Kris
Paul A Bunn
Ignacio I Wistuba
David J Kwiatkowski
Dwight H Owen
Yan Tang
Bruce E Johnson
Jay M Lee
Gerard Lozanski
Maciej Pietrzak
Michal Seweryn
Woo Yul Byun
Katja Schulze
Alan Nicholas
Ann Johnson
Jessica Grindheim
Stephanie Hilz
David S Shames
Chris Rivard
Eric Toloza
Eric B Haura
Ciaran J McNamee
G Alexander Patterson
Saiama N Waqar
Valerie W Rusch
David P Carbone

Publication Date

1-1-2024

Journal

Nature Medicine

DOI

10.1038/s41591-023-02627-7

PMID

37816821

PMCID

PMC10803254

PubMedCentral® Posted Date

10-10-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Recommended Citation

Chaft, Jamie E; Oezkan, Filiz; Kris, Mark G; et al., "Author Correction: Neoadjuvant Atezolizumab for Resectable Non-Small Cell Lung Cancer: An Open-Label, Single-Arm Phase II Trial" (2024). Faculty, Staff and Student Publications. 4391.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4391